Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

“…While a number of cytokines have been considered for use in anti-tumour therapy (including the use of GM-CSF or IL12 in oncolytic HSV vectors [39][40][41][42][43] ), GM-CSF has generally, and most reliably, given the best results when tested in comparison to other cytokines in pre-clinical models. Clinically, for cancer treatment, indications of efficacy have also been seen when GM-CSF has been delivered by a number of means (eg using engineered, re-injected primary tumour cells -'GVAX'; eg reference 44).…”

New insights into IL-12-mediated tumor suppression

“…Thus, delivery of IL-12 by electroporation or viral-based strategies reduced growth of established colon carcinoma, melanoma and brain tumors. [70][71][72][73][74] In the case of breast cancer, the success of IL-12 gene therapy was dependent on the immunogenicity of the tumor. Whereas IL-12 led to regression of highly immunogenic TS/A tumors, the growth of 4T1 tumors, which are considered less immunogenic, was not affected.…”

Stratégies génétiques, immunologiques et pharmacologiques au service d’une nouvelle génération de virus anticancéreux

“…Dans une approche similaire, le gène du symporteur de sodium/iodure (NIS) a été incorporé à plusieurs types de virus oncolytiques. La présence de NIS à la surface [25,26], ainsi qu'à une infiltration accrue de macrophages et de lymphocytes T CD4 + et CD8 + au sein la tumeur [27,28]. De façon intéressante, le gain thérapeutique a pu être amplifié en combinant la surexpression de cytokines à celle de molécules costimulatrices, telles que CD80/B7-1 ou 4-1BBL.…”